Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Lonza upgraded to Outperform from Sector Perform at RBC Capital » 04:56
05/20/22
05/20
04:56
05/20/22
04:56
LZAGY

Lonza

$54.98 /

+1.27 (+2.36%)

RBC Capital analyst…

RBC Capital analyst Charles Weston upgraded Lonza to Outperform from Sector Perform with a price target of CHF 650, down from CHF 720. The analyst expects supply and demand for biologic contract development and manufacturing will be "tightly matched" for through 2024 and says demand should then "materially exceed" supply from 2025. This de-risks long-term growth forecasts for Lonza, Weston tells investors in a research note.

ShowHide Related Items >><<
LZAGY Lonza
$54.98 /

+1.27 (+2.36%)

LZAGY Lonza
$54.98 /

+1.27 (+2.36%)

04/04/22 Morgan Stanley
Lonza price target lowered to CHF 785 from CHF 800 at Morgan Stanley
02/10/22 Stifel
Lonza upgraded to Buy from Hold at Stifel
01/04/22 JPMorgan
Lonza price target raised to CHF 900 from CHF 850 at JPMorgan
10/20/21 UBS
Lonza upgraded to Buy from Neutral at UBS
Thursday
Hot Stocks
Kodiak Sciences, Lonza announce opening of new bioconjugation facility » 08:16
05/19/22
05/19
08:16
05/19/22
08:16
KOD

Kodiak Sciences

$5.99 /

-0.1 (-1.64%)

, LZAGY

Lonza

$53.71 /

-1.89 (-3.40%)

Kodiak Sciences (KOD) and…

Kodiak Sciences (KOD) and Lonza (LZAGY) announced the opening of a new, custom-built, bioconjugation facility within Lonza's Ibex Dedicate manufacturing complex in Visp. The facility will play a key role in the scaled manufacturing of Kodiak's lead therapeutic candidate KSI-301 to support a potential global commercial launch. Once fully operational and if KSI-301 is approved for commercial use, the facility is expected to have the capacity to supply over 10 million dose equivalents of KSI-301 annually. The strong relationship between Kodiak and Lonza has led to a multi-year commercial collaboration that has created 12 full-time positions at Kodiak Sciences in Visp and 70 positions at Lonza.

ShowHide Related Items >><<
KOD Kodiak Sciences
$5.99 /

-0.1 (-1.64%)

KOD Kodiak Sciences
$5.99 /

-0.1 (-1.64%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LZAGY Lonza
$53.71 /

-1.89 (-3.40%)

04/04/22 Morgan Stanley
Lonza price target lowered to CHF 785 from CHF 800 at Morgan Stanley
02/10/22 Stifel
Lonza upgraded to Buy from Hold at Stifel
01/04/22 JPMorgan
Lonza price target raised to CHF 900 from CHF 850 at JPMorgan
10/20/21 UBS
Lonza upgraded to Buy from Neutral at UBS
KOD Kodiak Sciences
$5.99 /

-0.1 (-1.64%)

KOD Kodiak Sciences
$5.99 /

-0.1 (-1.64%)

Over a month ago
Recommendations
Lonza price target lowered to CHF 785 from CHF 800 at Morgan Stanley » 14:16
04/04/22
04/04
14:16
04/04/22
14:16
LZAGY

Lonza

$72.70 /

+0.21 (+0.29%)

Morgan Stanley analyst…

Morgan Stanley analyst James Quigley lowered the firm's price target on Lonza to CHF 785 from CHF 800 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$72.70 /

+0.21 (+0.29%)

LZAGY Lonza
$72.70 /

+0.21 (+0.29%)

02/10/22 Stifel
Lonza upgraded to Buy from Hold at Stifel
01/04/22 JPMorgan
Lonza price target raised to CHF 900 from CHF 850 at JPMorgan
10/20/21 UBS
Lonza upgraded to Buy from Neutral at UBS
10/15/21 Deutsche Bank
Lonza price target raised to CHF 835 from CHF 800 at Deutsche Bank
Over a quarter ago
Upgrade
Lonza upgraded to Buy from Hold at Stifel » 05:28
02/10/22
02/10
05:28
02/10/22
05:28
LZAGY

Lonza

$67.72 /

+1.335 (+2.01%)

Stifel analyst Bruno…

Stifel analyst Bruno Bulic upgraded Lonza to Buy from Hold with a price target of CHF 838, up from CHF 785, after taking over coverage of the name. The analyst has a positive view on the evolution of Lonza's margins and the upside from its biologics division, in particular the biosimilar segment.

ShowHide Related Items >><<
LZAGY Lonza
$67.72 /

+1.335 (+2.01%)

LZAGY Lonza
$67.72 /

+1.335 (+2.01%)

01/04/22 JPMorgan
Lonza price target raised to CHF 900 from CHF 850 at JPMorgan
10/20/21 UBS
Lonza upgraded to Buy from Neutral at UBS
10/15/21 Deutsche Bank
Lonza price target raised to CHF 835 from CHF 800 at Deutsche Bank
09/17/21 Morgan Stanley
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
Recommendations
Lonza price target raised to CHF 900 from CHF 850 at JPMorgan » 14:38
01/04/22
01/04
14:38
01/04/22
14:38
LZAGY

Lonza

$82.02 /

-1.48 (-1.77%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Lonza to CHF 900 from CHF 850 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$82.02 /

-1.48 (-1.77%)

LZAGY Lonza
$82.02 /

-1.48 (-1.77%)

10/20/21 UBS
Lonza upgraded to Buy from Neutral at UBS
10/15/21 Deutsche Bank
Lonza price target raised to CHF 835 from CHF 800 at Deutsche Bank
09/17/21 Morgan Stanley
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
Hot Stocks
Lonza to acquire Codiak BioSciences exosome manufacturing facility » 08:09
11/02/21
11/02
08:09
11/02/21
08:09
CDAK

Codiak

$15.18 /

+0.62 (+4.26%)

, LZAGY

Lonza

$83.74 /

+1.31 (+1.59%)

Lonza (LZAGY) announced…

Lonza (LZAGY) announced the acquisition of an exosome manufacturing facility located in Lexington, Massachusetts from Codiak BioSciences (CDAK). Codiak will retain its pipeline of therapeutic candidates as well as its exosome engineering and drug-loading technologies. Codiak will receive as part of the deal approximately $65M of cGMP manufacturing services in kind. Lonza will gain worldwide access and sub-licensable rights to Codiak's high-throughput perfusion-based cGMP process for exosome manufacturing. The companies will establish a Center of Excellence for the development of exosome manufacturing technologies. Alberto Santagostino, SVP, Head of Cell and Gene Technologies at Lonza, commented: "We are excited about the collaboration we have established with Codiak BioSciences. Exosomes are emerging as a new modality for advanced therapies and could become the next frontier in biotherapeutics. Our collaboration with Codiak, one of the most advanced companies in this modality, is consistent with our strategy to advance this technology and will drive the advancement of the whole industry. We are committed to providing our capabilities to Codiak, alongside other customers in the exosome space."

ShowHide Related Items >><<
CDAK Codiak
$15.18 /

+0.62 (+4.26%)

CDAK Codiak
$15.18 /

+0.62 (+4.26%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
LZAGY Lonza
$83.74 /

+1.31 (+1.59%)

10/20/21 UBS
Lonza upgraded to Buy from Neutral at UBS
10/15/21 Deutsche Bank
Lonza price target raised to CHF 835 from CHF 800 at Deutsche Bank
09/17/21 Morgan Stanley
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
CDAK Codiak
$15.18 /

+0.62 (+4.26%)

  • 12
    Feb
CDAK Codiak
$15.18 /

+0.62 (+4.26%)

Upgrade
Lonza upgraded to Buy from Neutral at UBS » 04:42
10/20/21
10/20
04:42
10/20/21
04:42
LZAGY

Lonza

$78.27 /

-0.17 (-0.22%)

UBS analyst Patrick…

UBS analyst Patrick Rafaisz upgraded Lonza to Buy from Neutral with a price target of CHF 830, up from CHF 610. The analyst sees a "compelling long-term growth story" and sees opportunity following the recent pullback in the shares. He views Lonza's valuation as attractive at current levels.

ShowHide Related Items >><<
LZAGY Lonza
$78.27 /

-0.17 (-0.22%)

10/15/21 Deutsche Bank
Lonza price target raised to CHF 835 from CHF 800 at Deutsche Bank
09/17/21 Morgan Stanley
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
Recommendations
Lonza price target raised to CHF 835 from CHF 800 at Deutsche Bank » 12:52
10/15/21
10/15
12:52
10/15/21
12:52
LZAGY

Lonza

$77.86 /

-0.1 (-0.13%)

Deutsche Bank analyst…

Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Lonza to CHF 835 from CHF 800 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$77.86 /

-0.1 (-0.13%)

09/17/21 Morgan Stanley
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
07/29/21 Deutsche Bank
Lonza price target raised to CHF 800 from CHF 680 at Deutsche Bank
Downgrade
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley » 07:34
09/17/21
09/17
07:34
09/17/21
07:34
LZAGY

Lonza

$84.25 /

+0.6 (+0.72%)

Morgan Stanley analyst…

Morgan Stanley analyst James Quigley downgraded Lonza to Equal Weight from Overweight with a price target of CHF 810, up from CHF 745.

ShowHide Related Items >><<
LZAGY Lonza
$84.25 /

+0.6 (+0.72%)

LZAGY Lonza
$84.25 /

+0.6 (+0.72%)

09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
07/29/21 Deutsche Bank
Lonza price target raised to CHF 800 from CHF 680 at Deutsche Bank
07/29/21 Societe Generale
Lonza price target raised to CHF 885 from CHF 830 at Societe Generale
Recommendations
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan » 12:37
09/08/21
09/08
12:37
09/08/21
12:37
LZAGY

Lonza

$84.04 /

-0.18 (-0.21%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Lonza to CHF 850 from CHF 680 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$84.04 /

-0.18 (-0.21%)

LZAGY Lonza
$84.04 /

-0.18 (-0.21%)

09/08/21 JPMorgan
Lonza price target raised to CHF 850 from CHF 680 at JPMorgan
07/29/21 Deutsche Bank
Lonza price target raised to CHF 800 from CHF 680 at Deutsche Bank
07/29/21 Societe Generale
Lonza price target raised to CHF 885 from CHF 830 at Societe Generale
07/28/21 Citi
Lonza price target raised to CHF 680 at Citi

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.